Koji Nagai
Overview
Explore the profile of Koji Nagai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
614
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nishimura N, Onishi A, Yamamoto W, Nagai K, Shiba H, Okita Y, et al.
Rheumatology (Oxford)
. 2024 Oct;
PMID: 39475445
Objectives: The impact of individual biological/targeted synthetic disease-modifying anti-rheumatic drug (b/tsDMARD) on kidney function in patients with rheumatoid arthritis (RA) remains unclear. This study aimed to determine the comparative effects...
2.
Shirasugi I, Onishi A, Nishimura K, Yamamoto W, Murakami K, Onizawa H, et al.
Int J Rheum Dis
. 2024 Mar;
27(3):e15097.
PMID: 38439176
Aim: To investigate the association of large joint involvement (LJI) with disease activity and drug retention in patients with rheumatoid arthritis (RA) who started receiving a biological disease-modifying antirheumatic drug...
3.
Ebina K, Etani Y, Maeda Y, Okita Y, Hirao M, Yamamoto W, et al.
RMD Open
. 2023 Aug;
9(3).
PMID: 37597846
Objectives: This multicentre retrospective study in Japan aimed to assess the retention of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors (JAKi), and to clarify the factors affecting their retention...
4.
Shiba H, Kotani T, Nagai K, Hata K, Yamamoto W, Yoshikawa A, et al.
Int J Mol Sci
. 2023 Apr;
24(8).
PMID: 37108561
This multicenter retrospective study aimed to clarify the prognostic factors for mortality and changes in treatment modalities and disease activities after the onset of pneumonia (PCP) in patients with rheumatoid...
5.
Makino H, Kotani T, Hata K, Nishioka D, Yamamoto W, Yoshikawa A, et al.
Mod Rheumatol
. 2022 Sep;
33(5):928-935.
PMID: 36112486
The aim of this multi-centre retrospective study was to clarify the prognostic factors for respiratory-related death in patients with interstitial lung disease (ILD) complicated rheumatoid arthritis (RA). Patient background data,...
6.
Murata K, Uozumi R, Hashimoto M, Ebina K, Akashi K, Onishi A, et al.
Mod Rheumatol
. 2021 Dec;
32(4):834-838.
PMID: 34910199
Objectives: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by localized and generalized bone loss. The risk of fractures is doubled in patients with RA. Denosumab, an anti-RANKL monoclonal...
7.
Onishi A, Akashi K, Yamamoto W, Ebina K, Murata K, Hara R, et al.
Am J Kidney Dis
. 2021 May;
78(5):761-764.
PMID: 33984404
No abstract available.
8.
Matsuda S, Kotani T, Suzuka T, Kiboshi T, Fukui K, Wakama M, et al.
Sci Rep
. 2021 Jan;
11(1):1490.
PMID: 33452394
The prognosis of microscopic polyangiitis (MPA) with interstitial lung disease (ILD) is significantly worse than that of MPA without ILD. However, the clinical characteristics in MPA-ILD, especially poor prognostic factors,...
9.
Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, et al.
Clin Rheumatol
. 2020 Mar;
39(9):2563-2572.
PMID: 32162152
Objectives: The aim of this multicenter, retrospective study was to clarify the retention of secondary biological disease-modifying antirheumatic drugs (bDMARDs) or Janus kinase inhibitors (JAKi) in patients with rheumatoid arthritis...
10.
Hirohi T, Ng D, Nagai K, Yoshimura K
Plast Reconstr Surg
. 2019 Nov;
144(6):1108e-1109e.
PMID: 31764683
No abstract available.